71 related articles for article (PubMed ID: 3841501)
1. Tastes associated with parenteral chemotherapy for breast cancer.
Fetting JH; Wilcox PM; Sheidler VR; Enterline JP; Donehower RC; Grochow LB
Cancer Treat Rep; 1985 Nov; 69(11):1249-51. PubMed ID: 3841501
[TBL] [Abstract][Full Text] [Related]
2. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
Wilcox PM; Fetting JH; Nettesheim KM; Abeloff MD
Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
[TBL] [Abstract][Full Text] [Related]
3. Anticipatory nausea and vomiting in an ambulatory medical oncology population.
Fetting JH; Wilcox PM; Iwata BA; Criswell EL; Bosmajian LS; Sheidler VR
Cancer Treat Rep; 1983 Dec; 67(12):1093-8. PubMed ID: 6652626
[TBL] [Abstract][Full Text] [Related]
4. [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Ishida T; Kusaba T; Hayakawa H
Gan To Kagaku Ryoho; 2002 May; 29(5):723-8. PubMed ID: 12040676
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity.
Zachariae R; Paulsen K; Mehlsen M; Jensen AB; Johansson A; von der Maase H
Psychother Psychosom; 2007; 76(6):376-84. PubMed ID: 17917474
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
Taguchi T; Tsukamoto F; Watanabe T; Yoneda K; Takamura Y; Hojo S; Shiba E; Noguchi S
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1163-70. PubMed ID: 10431583
[TBL] [Abstract][Full Text] [Related]
7. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
[TBL] [Abstract][Full Text] [Related]
8. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
10. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
11. Dehydropyrimidine dehydrogenase deficiency in a cancer patient undergoing 5-fluorouracil chemotherapy.
Schneider HB; Becker H
Anticancer Res; 2004; 24(2C):1091-2. PubMed ID: 15154628
[TBL] [Abstract][Full Text] [Related]
12. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Kim SJ; Taguchi T; Miyoshi Y; Tanji Y; Tamaki Y; Noguchi S
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1919-23. PubMed ID: 16282727
[TBL] [Abstract][Full Text] [Related]
13. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
14. Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.
Cadman EC; Glick JH; Cross J; Horton J; Taylor SG
Cancer Treat Rep; 1984 Jun; 68(6):877-9. PubMed ID: 6547367
[TBL] [Abstract][Full Text] [Related]
15. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
17. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
18. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
Ruffert K
Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
[TBL] [Abstract][Full Text] [Related]
19. [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events].
Kodama F; Mohri H; Motomura S; Fukawa H; Tanabe J; Koharasawa H; Kanamori H; Hashimoto Y; Harano H; Sakai R; Tomita N; Fujimaki K; Takemura S; Hattori M
Gan To Kagaku Ryoho; 2002 Feb; 29(2):273-9. PubMed ID: 11865634
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
